http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
폐플라스틱 재활용 방법의 경제성 분석 : 폐스티로폴 재활용을 중심으로
전상일,양봉민 한국환경정책학회 1997 環境政策 Vol.5 No.1
With the increasing use of EPS(expandable polystyrene, stroper), there has been troublesome in disposal of the waste styropor because the styropor hardly decays, takes up too much space for its weight, and prevent the soil structure from being stabilized when duried. In the meanwhile, the styropor was Chosen to be a separate collection item the bv the gorvernment since 1996 and the recycling process of the waste styropor was developed. In this paper we analyzed the economic propriety of a recycling method of the wastes styropor in Seoul through the coat-benefit analysis. The results are as follows. The" sum of benefits is larger than that of costs by 1~3times. But here, we have to consider that the value of the benefit side was underestimated because it's almost impossible to value the invisible benefits owing to the lack of resenable data while the sector was fully estimated. Putting all the results together, we can come to the conclusion that the recycling of the waste styropor has much value in view of social welfare. And we proposed several supplemental policies to promote the recycling works and to overcome market failure. Of all things, the governmental support is considered to be the most important in light of the disadvantages of the recycled products.
전상일,이헌상 한국물리학회 2012 Current Applied Physics Vol.12 No.2
The electrical conductivity of amorphous polymer/multiwall carbon nanotube (MWCNT) composite films strongly depends on the Bernard-Marangoni (B-M) instability during solvent evaporation. We demonstrate that the films exhibit the lowest surface resistivity and the highest light transmittance near the onset point of B-M instability. The polymer/MWCNT composite films exhibit three-dimensional behavior in spite of the B-M instability. The percolation threshold for PC/MWCNT composite films at stable, onset,and unstable condition is 3.3 × 10-3, 2.75 × 10-3, and 5.15 × 10-3 vol.%, respectively.
건강한 성인 남성을 대상으로 Levodropropizine CR정반복 투여시의 약동학적 특성 및 안전성에 관한 연구
전상일,이종태,홍태곤,백정기,한승훈,임동석 대한임상약리학회 2013 Translational and Clinical Pharmacology Vol.21 No.2
Background: Levodropropizine is non-opioid agent whose peripheral antitussive action may result from its modulation of sensory neuropeptide levels. Currently, levodropropizine 60 mg is taken three-times daily. A controlled release formulation of levodropropizine (levodropropizine CR) 90 mg was developed, which can be taken twice daily. The aim of this study was to evaluate the safety and pharmacokinetic characteristics after multiple oral administrations of levodropropizine CR 90 mg tablets in healthy male volunteers. Methods: A randomized, open-label, cross-over study was conducted in 24 healthy male volunteers. Each subject received levodropropizine syrup 60 mg three times daily or levodropropizine CR 90 mg twice daily for 3 days. Blood samples for pharmacokinetic analysis were collected pre-dose and up to 24 hours on day 4. Pharmacokinetic analysis was conducted by non-compartmental method. Safety assessments including monitoring adverse events, laboratory tests, vital signs, physical examinations and ECGs were performed throughout the study. Results: A total of 20 male volunteers completed the study. The maximum steady-state plasma concentration (Css,max) of levodropropizine syrup and levodropropizine CR were 313.28 ng/mL and 285.31 ng/mL and time to reach Css,max (Tmax,ss) were 0.48 hr and 0.88 hr, respectively. The area under the concentration-time curve to the last measured concentration of two groups were 2345.36 hr × ng/mL and 2553.81 hr × ng/mL, respectively. There was no serious adverse event. Conclusion: Levodropropizine CR 90 mg tablet was safe and well-tolerated when administered twice daily for 3 days. No statistically significant differences were seen in Css,max and AUCss,24hr between the two formulations. This study provided pharmacokinetic evidences that the twice-daily dosing regimen of levodropropizine 90 mg may substitute the conventional 3-times-daily regimen of levodropropizine 60 mg.